ALFA News
Straight from the exchange filing
Every announcement Glenmark Pharmaceuticals has filed with the exchanges that we have reported, newest first. Each story links the original filing.
Every Glenmark Pharmaceuticals announcement on ALFA FilingsSee filings →Reference market data from a third-party provider, as of the most recent story. Not a valuation or a recommendation.
Glenmark Pharmaceuticals launches Adapalene Gel USP 0.1% OTC pump packs in the US, targeting a $45.8M market while reporting a 930% YoY jump in quarterly profit.
Glenmark Pharmaceuticals launches RYALTRIS nasal spray in Brazil, targeting a patient pool of 60 million. The product is now approved in 57 global markets.
Glenmark Pharmaceuticals launches Calcium Gluconate Injection USP in the US, targeting a $69.9M market. This expands the company's hospital product portfolio.
Glenmark Pharmaceuticals initiates Phase 3 enrollment in India for Trastuzumab rezetecan, targeting ovarian cancer. TTM revenue stands at ₹16,982.51 Cr.
Glenmark Pharmaceuticals launches Lacosamide Injection USP in the US market, targeting annual sales of $15.2 million. Learn about this strategic portfolio expansion.
